PD-170262

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NamePD-170262
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor inhibitors
TargetsPlatelet-derived growth factor
Therapy Area/IndicationsPsoriasisAtherosclerosisCoronary Restenosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsPsoriasisAtherosclerosisCoronary Restenosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A